Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Clinical trial NCT01089101 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01089101
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Low Grade Glioma Recurrent Childhood Pilocytic Astrocytoma Recurrent Neurofibromatosis Type 1 Recurrent Visual Pathway Glioma Refractory Neurofibromatosis Type 1 Refractory Visual Pathway Glioma

Start date: 2010-07-07
Primary completion: 2026-01-17
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.